Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.

IF 2.7 3区医学 Q3 ONCOLOGY Acta Oncologica Pub Date : 2024-05-06 DOI:10.2340/1651-226X.2024.24377

Aino Rajamaki, Marc Sorigue, Roosa E I Prusila, Milla E L Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen

{"title":"Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.","authors":"Aino Rajamaki, Marc Sorigue, Roosa E I Prusila, Milla E L Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen","doi":"10.2340/1651-226X.2024.24377","DOIUrl":null,"url":null,"abstract":"Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies.Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of therapy on the basis of relevant biological characteristics and therapeutic choices. Patients (n = 743, 51% females, median 60 years old) diagnosed with grade 1-2 FL between 1997 and 2016 in nine institutions were included.Results: The median PFS1, PFS2, and PFS3 were 8.1 years (95% confidence interval [CI]: 7-9.3 years), 4.2 years (95% CI: 2.8-5.6 years) and 2.2 years (95% CI 1.7-2.8 years). We found longer PFS1 for (1) females, (2) younger age, (3) lower-risk follicular lymphoma international prognostic index (FLIPI), (4) standard intensity (over low intensity) regimens and (5) immunochemotherapy strategies and (6) maintenance rituximab. We found a shorter PFS2 for patients who received front-line immunochemotherapy. Older age at diagnosis correlated with a shorter PFS3. Intensity of front-line chemotherapy, maintenance, or POD24 status did not correlate with PFS2 or PFS3 in this dataset.Interpretation: With current immunochemotherapy strategies, the natural course of FL is characterized by shorter-lasting remissions after each relapse. It will be interesting to see whether new therapies can alter this pattern.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"267-272"},"PeriodicalIF":2.7000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332539/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Oncologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/1651-226X.2024.24377","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies.

Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of therapy on the basis of relevant biological characteristics and therapeutic choices. Patients (n = 743, 51% females, median 60 years old) diagnosed with grade 1-2 FL between 1997 and 2016 in nine institutions were included.

Results: The median PFS1, PFS2, and PFS3 were 8.1 years (95% confidence interval [CI]: 7-9.3 years), 4.2 years (95% CI: 2.8-5.6 years) and 2.2 years (95% CI 1.7-2.8 years). We found longer PFS1 for (1) females, (2) younger age, (3) lower-risk follicular lymphoma international prognostic index (FLIPI), (4) standard intensity (over low intensity) regimens and (5) immunochemotherapy strategies and (6) maintenance rituximab. We found a shorter PFS2 for patients who received front-line immunochemotherapy. Older age at diagnosis correlated with a shorter PFS3. Intensity of front-line chemotherapy, maintenance, or POD24 status did not correlate with PFS2 or PFS3 in this dataset.

Interpretation: With current immunochemotherapy strategies, the natural course of FL is characterized by shorter-lasting remissions after each relapse. It will be interesting to see whether new therapies can alter this pattern.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

临床实践中，滤泡性淋巴瘤患者在一线、二线和三线治疗后的无进展生存期。

背景：滤泡性淋巴瘤（FL）的现代疗法包括多种高效疗法：我们根据相关生物学特征和治疗选择，确定一线、二线和三线治疗后的无进展生存期（PFS）。研究纳入了1997年至2016年期间在9家机构确诊为1-2级FL的患者（n = 743，51%为女性，中位年龄60岁）：中位 PFS1、PFS2 和 PFS3 分别为 8.1 年（95% 置信区间 [CI]：7-9.3 年）、4.2 年（95% CI：2.8-5.6 年）和 2.2 年（95% CI：1.7-2.8 年）。我们发现，(1) 女性；(2) 年龄较小；(3) 低风险滤泡性淋巴瘤国际预后指数（FLIPI）；(4) 标准强度（高于低强度）方案；(5) 免疫化疗策略；(6) 利妥昔单抗维持治疗的 PFS1 较长。我们发现，接受一线免疫化疗的患者的 PFS2 较短。诊断时的高龄与较短的 PFS3 相关。在该数据集中，一线化疗强度、维持治疗或POD24状态与PFS2或PFS3无关：在目前的免疫化疗策略下，FL的自然病程特点是每次复发后的缓解持续时间较短。新疗法是否能改变这种模式将是一个有趣的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Acta Oncologica 医学-肿瘤学

CiteScore

4.30

自引率

3.20%

发文量

301

审稿时长

3 months

期刊介绍： Acta Oncologica is a journal for the clinical oncologist and accepts articles within all fields of clinical cancer research. Articles on tumour pathology, experimental oncology, radiobiology, cancer epidemiology and medical radio physics are also welcome, especially if they have a clinical aim or interest. Scientific articles on cancer nursing and psychological or social aspects of cancer are also welcomed. Extensive material may be published as Supplements, for which special conditions apply.